Navigation Links
Dendreon Announces Presentation of Data at American Urological,Association Annual Meeting

mized Phase 3 trials (D9901 and D9902A; n=225) conducted in men with asymptomatic, metastatic, androgen independent prostate cancer. Survival analyses were performed on the subgroup of 82 patients in the trials that were documented to have received docetaxel chemotherapy following initial treatment with either PROVENGE or placebo.

According to the analysis, the patients who received initial treatment with PROVENGE followed by docetaxel had a median survival of 34.5 months compared to 25.4 months for those patients in the placebo arm who received treatment with docetaxel chemotherapy, a 9.1 month difference. In addition, an analysis of overall survival demonstrated that patients in the PROVENGE arm who received subsequent therapy with docetaxel had a 47 percent reduction in their risk of death compared to those in the placebo arm who received subsequent therapy with docetaxel (HR = 1.90, p-value = 0.023).

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007, and more than 27,000 men expected to die this year from the disease.

About PROVENGE

PROVENGE (sipuleucel-T) is an investigational product that may represent the first in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. PROVENGE is in late-stage clinical development for the treatment of patients with early-stage and advanced prostate cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the im
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/6/2009)...swire-FirstCall/ -- Derma Sciences, Inc. (OTC ...d care products, announced plans to release its th...November 16, 2009. The Company will hold a confere...1:00 am EST. Interested parties should call (866) ...al), with passcode 81416481 to access the call. Yo...
(Date:11/6/2009)...FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA ), a m...ts for minimally disruptive surgical treatments fo...chael J. Lambert as Executive Vice President and C.... The Company also announced several other Execut...e an excellent complement to the NuVasive family,"...
(Date:11/6/2009)...wire-FirstCall/ -- Virtual Health Technologies, In... the previously confirmed Letter of Intent to sell...t Technologies, Inc (WNDM) is subject to final app...of VHGI. ,, Shareholder Assurances ,, "W...ty stream and cash realized from the transaction w...
Breaking Medicine Technology:Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4Fraternal Order of Eagles Award 24630 000 in Grants at International Convention 51809 1Fraternal Order of Eagles Award 24630 000 in Grants at International Convention 51809 2Tube Feeding Error 3A Fatal Medical Mistakes 51804 1Tube Feeding Error 3A Fatal Medical Mistakes 51804 2Tube Feeding Error 3A Fatal Medical Mistakes 51804 3Aprima Medical Software Inc Unveiled by iMedica 3B Premier EHR PM Company Adopts New Name 51802 1Aprima Medical Software Inc Unveiled by iMedica 3B Premier EHR PM Company Adopts New Name 51802 2Aprima Medical Software Inc Unveiled by iMedica 3B Premier EHR PM Company Adopts New Name 51802 3
...abase Developed in West Michigan to Help Advanc... Netherlands and GRAND RAPIDS, Mich., Feb. 14 The...ed the formation of a,collaborative effort with it...t, Prime Standard: QIA) to support research focuse...elping diagnose breast cancer and other,women,s he...
...uticals Limited (ASX: PGL; Nasdaq: PGLA) today ann...a phase 2 investigator-initiated trial of,PI-88 in...ere(R),(docetaxel) administered to patients with p...ospital, Sydney Haematology and Oncology Clinics, ...ill present the preliminary,results of the study t...
Other Medicine Technology:QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 2QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 3QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 4Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium 2Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium 3
(Date:11/6/2009)...ill Will Drive Unemployment Higher Says Small Busi...SNewswire/ -- With the unemployment rate now sho...l small business leader warned the U.S. House that...o further job loss and a deterioration of the smal...Business & Entrepreneurship Council (SBE Counc...
(Date:11/6/2009)...v. 6 With the number of premature ...g in the U.S., a basic eye exam, including a red r...y after birth, reports Angela Buffenn, M.D., M.P.H...e at The Vision Center of Childrens Hospital Los A...any medically fragile infants to survive. Unfortun...
(Date:11/6/2009)...ov. 6 In a newly-published special... calls for new hospital policies to prevent and tr... death and disability in hospitals throughout the ...s publishing the supplement to bring attention to ...al condition of deep vein thrombosis and its most ...
(Date:11/6/2009)...ov. 6 The American Academy of Nurs...rd members of Lippincott Williams & Wilkins (L...s part of Wolters Kluwer Health, a leading provide...dents, professionals, and institutions in medicine...llows are selected based on evidence of significan...
(Date:11/6/2009)... Lockton Benefit Group, the health ...panies, LLC, today announced employer health cost ...nt in collaboration with U.S.-based healthcare com...com/cgi-bin/prnh/20090415/CG99351LOGO ) ,, Lock...support Lockton,s clients with: ,, Health prom...
Breaking Medicine News(10 mins):Health News:Pelosi to House: Let's Destroy More Jobs 2Health News:Red Reflex Vision Exam Should Be Given to All Newborns, Report Recommends 2Health News:Red Reflex Vision Exam Should Be Given to All Newborns, Report Recommends 3Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 2Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 3Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 2Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 3Health News:Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 2Health News:Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 3
... of the bird flu vaccine a "fundamental ethical di... get the injections first//. While health staf...rity group a research published in Science calls f...sues were to ‘decrease health impacts’ including i...
... the organ donation rate in UK is one of the lowes... are reluctant to allow such procedures. // This w...wishes of potential organ donors because they are ...year audit, said that certain families were refusi...
...largest health insurer has cut down payments for h...dical society has requested investigation //in to ...ians and other providers due to which independent ...J. Joseph Curran Jr. that they were losing clients...
...distributed to Health workers by the Ontario gover...has attracted a lot of flak from critics // , who ...ncere attempt at combating a flu pandemic. The op...00 emergency kits will be distributed across Ontar...
... revealed that the blood of patients with head and...expression which could serve as a screening test f...omparing protein expression in 78 patients with he...nd scores and scores of proteins that were differe...
... Journal has launched a website for providing info... site (http://www.besttreatments.co.uk) is designe...ormation. // Concerned about number of peopl...te. It has sections on men's, women's and ch...
Other Medicine News:Health News:Young or Old-Who should be first? 2Health News:Grieving Relatives Reluctant To Give Consent For Organ Donation 2Health News:Protein Expression to Serve as Marker for Head and Neck Cancer 2Health News:Protein Expression to Serve as Marker for Head and Neck Cancer 3
STA FIBRINOGEN 5
STA NEOPLASTINE CI + 10 (ISI ~ 1.3)
Albumin (BCP-DIMENSION)
Phosohorus (Inorganic)
Medicine Products: